Table 2 Maximum response.

From: Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

Maximum response

ICD (n = 57)

CD (n = 53)

Total (n = 110)

CR

1 (1.8%)

1 (1.9%)

2 (1.8%)

VGPR

8 (14.0%)

5 (9.4%)

13 (11.8%)

PR

15 (26.3%)

15 (28.3%)

30 (27.3%)

MR

9 (15.8%)

6 (11.3%)

15 (13.6%)

SD or NC

14 (24.6%)

18 (34.0%)

32 (29.1%)

PD

7 (12.3%)

4 (7.5%)

11 (10.0%)

No maximum response

3 (5.3%)

4 (7.5%)

7 (6.4%)